Fast Five Quiz: Long-Acting Injectable Antipsychotics

Ravinder N. Bhalla, MD


August 19, 2021

A recently published study showed that among patients newly diagnosed with schizophrenia, use of LAI antipsychotics was associated with significantly reduced risks of all-cause mortality and suicide attempts vs oral antipsychotics. Moreover, early treatment with LAIs (within the first 2 years after diagnosis) was also associated with decreased suicide mortality risks, suggesting that consideration of LAIs in the early stage of treatment is merited.

Learn more about the association of LAI antipsychotics and suicide risk.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.